Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KURA Stock Forecast 2025-2026
$11.95
Current Price
$1.04B
Market Cap
Buy 13
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to KURA Price Targets
+536.0%
To High Target of $76.00
+134.3%
To Median Target of $28.00
+33.9%
To Low Target of $16.00
KURA Price Momentum
-1.6%
1 Week Change
+21.2%
1 Month Change
+12.0%
1 Year Change
+37.2%
Year-to-Date Change
-4.3%
From 52W High of $12.49
+120.9%
From 52W Low of $5.41
📊 TOP ANALYST CALLS
Did KURA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Kura Oncology is one of their latest high-conviction picks.
Latest KURA Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, KURA has a bullish consensus with a median price target of $28.00 (ranging from $16.00 to $76.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $11.95, the median forecast implies a 134.3% upside. This outlook is supported by 13 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by David Dai at UBS, suggesting a 33.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KURA Analyst Ratings
13
Buy
2
Hold
0
Sell
KURA Price Target Range
Low
$16.00
Average
$28.00
High
$76.00
Current: $11.95
Latest KURA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KURA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 24, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $28.00 |
| Nov 14, 2025 | Wedbush | Robert Driscoll | Outperform | Maintains | $38.00 |
| Nov 14, 2025 | UBS | David Dai | Buy | Maintains | $16.00 |
| Oct 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $40.00 |
| Oct 20, 2025 | JMP Securities | Reni J. Benjamin | Market Outperform | Reiterates | $24.00 |
| Sep 30, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $40.00 |
| Sep 4, 2025 | Guggenheim | Brad Canino | Neutral | Initiates | $N/A |
| Aug 11, 2025 | JMP Securities | Reni J. Benjamin | Market Outperform | Maintains | $24.00 |
| Jun 26, 2025 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $N/A |
| Jun 20, 2025 | Wedbush | Robert Driscoll | Outperform | Reiterates | $36.00 |
| Jun 4, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $28.00 |
| May 19, 2025 | Mizuho | Mara Goldstein | Outperform | Maintains | $30.00 |
| May 2, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $11.00 |
| Apr 29, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $28.00 |
| Apr 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $40.00 |
| Mar 6, 2025 | UBS | David Dai | Buy | Maintains | $14.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $40.00 |
| Feb 6, 2025 | Wedbush | Robert Driscoll | Outperform | Maintains | $36.00 |
| Feb 6, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $40.00 |
| Feb 6, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $28.00 |
Kura Oncology Inc. (KURA) Competitors
The following stocks are similar to Kura Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kura Oncology Inc. (KURA) Financial Data
Kura Oncology Inc. has a market capitalization of $1.04B with a P/E ratio of -5.9x. The company generates $104.03M in trailing twelve-month revenue with a -208.5% profit margin.
Revenue growth is +35.7% quarter-over-quarter, while maintaining an operating margin of -385.5% and return on equity of -65.1%.
Valuation Metrics
Market Cap
$1.04B
Enterprise Value
$509.66M
P/E Ratio
-5.9x
PEG Ratio
-0.2x
Price/Sales
10.0x
Growth & Margins
Revenue Growth (YoY)
+35.7%
Gross Margin
N/A
Operating Margin
-385.5%
Net Margin
-208.5%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+52.9%
Current Ratio
5.1x
Debt/Equity
8.0x
ROE
-65.1%
ROA
-26.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Kura Oncology Inc. (KURA) Business Model
About Kura Oncology Inc.
What They Do
Develops precision medicines for cancer treatment.
Business Model
Kura Oncology operates as a clinical-stage biopharmaceutical company focused on creating targeted therapies for cancer by developing small molecule compounds that inhibit specific oncogenic pathways. The company generates revenue primarily through investments, partnerships, and potential future sales of its innovative cancer treatments once they receive regulatory approval.
Additional Information
With a pipeline that includes products like tipifarnib, Kura targets both hematologic malignancies and solid tumors. The company collaborates with leading research institutions to advance clinical trials, reflecting its commitment to enhancing cancer treatment strategies through precision medicine. Headquartered in San Diego, California, Kura is positioned within a growing sector of the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
192
CEO
Dr. Troy Edward Wilson J.D., Ph.D.
Country
United States
IPO Year
2015
Website
kuraoncology.comKura Oncology Inc. (KURA) Latest News & Analysis
Latest News
Quick Summary
Kura Oncology announced its first U.S. sale of KOMZIFTI™, triggering a $135 million payment from Kyowa Kirin, expected by year-end. The drug was FDA approved on November 13, 2025.
Why It Matters
Kura Oncology's first U.S. sale of KOMZIFTI triggers a $135 million payment, enhancing its financial position and signaling market potential for its cancer treatment, which can positively influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kura Oncology will host a virtual analyst and investor event on Dec. 8, 2025, to discuss data on ziftomenib with venetoclax and azacitidine for acute myeloid leukemia, ahead of the ASH Annual Meeting.
Why It Matters
Kura Oncology's upcoming event may impact stock performance by providing insights into promising clinical data for a new cancer treatment, influencing investor sentiment and potential market value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kura Oncology is rated a Strong Buy, bolstered by Ziftomenib's safety profile and AML market potential. Upcoming Phase 1b KOMET-007 data may impact investor sentiment.
Why It Matters
Kura Oncology's Ziftomenib presents a competitive advantage due to its safety profile, potentially boosting its market position. Upcoming data may lead to price volatility, impacting investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
KOMZIFTI, the first FDA-approved once-daily menin inhibitor for relapsed/refractory NPM1-mutated AML, is now available for commercial use in the U.S.
Why It Matters
The commercial launch of KOMZIFTI, a unique FDA-approved treatment for a specific type of leukemia, could lead to increased revenue for the company, impacting its stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kura Oncology announced FDA approval for KOMZIFTI, a treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, during a conference call on November 13, 2025.
Why It Matters
FDA approval of KOMZIFTI for a specific leukemia treatment can boost Kura Oncology's market position, potentially increasing stock value and attracting investor interest.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The FDA has approved Kura Oncology's drug for treating a rare blood cancer that has recurred or resisted initial therapy.
Why It Matters
FDA approval of Kura Oncology's drug can lead to increased revenue, boost stock prices, and enhance market confidence, signaling potential growth in the biotech sector.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About KURA Stock
What is Kura Oncology Inc.'s (KURA) stock forecast for 2026?
Based on our analysis of 21 Wall Street analysts, Kura Oncology Inc. (KURA) has a median price target of $28.00. The highest price target is $76.00 and the lowest is $16.00.
Is KURA stock a good investment in 2026?
According to current analyst ratings, KURA has 13 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KURA stock?
Wall Street analysts predict KURA stock could reach $28.00 in the next 12 months. This represents a 134.3% increase from the current price of $11.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kura Oncology Inc.'s business model?
Kura Oncology operates as a clinical-stage biopharmaceutical company focused on creating targeted therapies for cancer by developing small molecule compounds that inhibit specific oncogenic pathways. The company generates revenue primarily through investments, partnerships, and potential future sales of its innovative cancer treatments once they receive regulatory approval.
What is the highest forecasted price for KURA Kura Oncology Inc.?
The highest price target for KURA is $76.00 from at , which represents a 536.0% increase from the current price of $11.95.
What is the lowest forecasted price for KURA Kura Oncology Inc.?
The lowest price target for KURA is $16.00 from David Dai at UBS, which represents a 33.9% increase from the current price of $11.95.
What is the overall KURA consensus from analysts for Kura Oncology Inc.?
The overall analyst consensus for KURA is bullish. Out of 21 Wall Street analysts, 13 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $28.00.
How accurate are KURA stock price projections?
Stock price projections, including those for Kura Oncology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 9:21 AM UTC